Shimadzu Steps into Void, Brings Edman Sequencers to North America | GenomeWeb

This story has been updated from a previous version

Six months after researchers in the United States were left without a manufacturer and supplier of new Edman sequencers, Shimadzu will be bringing the instrument overseas, company officials told ProteoMonitor last week.

Shimadzu is making its Edman sequencers available in North America for the first time in its history, as part of an effort to expand its life-science footprint in that geography, more than 20 years after the company launched its first Edman sequencer in Japan.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.